Recent Posts
- Sanofi to acquire Provention Bio, adding to portfolio TZIELD, the first disease-modifying treatment for the delay of Stage 3 type 1 diabetes (T1D)
- MDB Capital Holdings Announces Third MDB-Launched Company to Achieve FDA Approval
- Public Ventures LLC Completes First Public Company Financing as a Broker-Dealer for Cue Biopharma, Inc. (Nasdaq:CUE)
- MDB Capital Holdings Announces Filing of Registration Statement for Proposed Offering and Listing on Nasdaq
- Lou Basenese Joins MDB Capital Holdings as President and Chief Market Strategist
Recent Comments